Welcome to our dedicated page for Centessa Pharmaceuticals Plc news (Ticker: CNTA), a resource for investors and traders seeking the latest updates and insights on Centessa Pharmaceuticals Plc stock.
Centessa Pharmaceuticals plc (Nasdaq: CNTA) is a clinical-stage pharmaceutical company centered on developing orexin receptor 2 (OX2R) agonist therapies for sleep–wake and neuroscience-related disorders. The CNTA news feed highlights company announcements that track the progress of this multi-asset OX2R pipeline and related corporate developments.
Investors and followers of Centessa can use this page to review news about the Phase 2a CRYSTAL‑1 study of ORX750 in narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH), as well as updates on the Phase 1 program for ORX142 in healthy volunteers and IND-enabling work for ORX489 in neuropsychiatric disorders. The company’s releases also describe preclinical data on additional OX2R agonists, including findings in animal models relevant to neuropsychiatric indications.
Beyond clinical milestones, CNTA news items cover capital markets and corporate events such as public offerings of American Depositary Shares, at-the-market sales agreements, participation in healthcare and investor conferences, and leadership changes reported via press release and Form 8‑K. These disclosures provide context on how Centessa funds and organizes its development activities.
This news page aggregates official communications from Centessa and related SEC-reported events, allowing readers to follow clinical data readouts, regulatory milestones like IND clearance, financing transactions and strategic updates around the company’s orexin-focused franchise. For ongoing research into CNTA, this stream offers a centralized view of the company’s reported progress and key announcements over time.
Transgene (Euronext Paris: TNG) has proposed Carol Stuckley as an independent Director, enhancing its corporate governance with an emphasis on director independence and gender diversity. Stuckley, a seasoned financial executive with over 35 years of experience, is currently a Board Director at Centessa Pharmaceuticals and has held key roles at Ipsen and Galderma North America. This nomination comes after the resignation of Laurence Espinasse. Shareholders will vote on Stuckley's appointment at the General Meeting scheduled for May 5, 2023. If approved, Transgene's Board will consist of 10 members, 6 of whom will be independent, contributing diverse skills aligned with its strategic needs.
FAQ
What is the current stock price of Centessa Pharmaceuticals Plc (CNTA)?
What is the market cap of Centessa Pharmaceuticals Plc (CNTA)?
